Your browser doesn't support javascript.
loading
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Karschnia, Philipp; Dono, Antonio; Young, Jacob S; Juenger, Stephanie T; Teske, Nico; Häni, Levin; Sciortino, Tommaso; Mau, Christine Y; Bruno, Francesco; Nunez, Luis; Morshed, Ramin A; Haddad, Alexander F; Weller, Michael; van den Bent, Martin; Beck, Juergen; Hervey-Jumper, Shawn; Molinaro, Annette M; Tandon, Nitin; Rudà, Roberta; Vogelbaum, Michael A; Bello, Lorenzo; Schnell, Oliver; Grau, Stefan J; Chang, Susan M; Berger, Mitchel S; Esquenazi, Yoshua; Tonn, Joerg-Christian.
Afiliação
  • Karschnia P; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany.
  • Dono A; German Cancer Consortium (DKTK), Partner Site Munich, Germany.
  • Young JS; Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, Texas, USA.
  • Juenger ST; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • Teske N; Department of Neurosurgery, University of Cologne, Cologne, Germany.
  • Häni L; Department of Neurosurgery, Ludwig-Maximilians-University, Munich, Germany.
  • Sciortino T; Department of Neurosurgery, University of Freiburg, Freiburg, Germany.
  • Mau CY; Division of Neuro-Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Bruno F; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Nunez L; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Italy.
  • Morshed RA; Department of Diagnostic and Interventional Imaging, McGovern Medical School at UT Health Houston, Houston, Texas, USA.
  • Haddad AF; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • Weller M; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • van den Bent M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
  • Beck J; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Hervey-Jumper S; Department of Neurosurgery, University of Freiburg, Freiburg, Germany.
  • Molinaro AM; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • Tandon N; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • Rudà R; Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, Texas, USA.
  • Vogelbaum MA; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Italy.
  • Bello L; Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Schnell O; Division of Neuro-Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Grau SJ; Department of Neurosurgery, University of Freiburg, Freiburg, Germany.
  • Chang SM; Department of Neurosurgery, University of Cologne, Cologne, Germany.
  • Berger MS; Klinikum Fulda, Academic Hospital of Marburg University, Klinikum, Fulda, Germany.
  • Esquenazi Y; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
  • Tonn JC; Department of Neurosurgery and Division of Neuro-Oncology, University of San Francisco, San Francisco, California, USA.
Neuro Oncol ; 25(9): 1672-1685, 2023 09 05.
Article em En | MEDLINE | ID: mdl-37253096
ABSTRACT

BACKGROUND:

The value of re-resection in recurrent glioblastoma remains controversial as a randomized trial that specifies intentional incomplete resection cannot be justified ethically. Here, we aimed to (1) explore the prognostic role of extent of re-resection using the previously proposed Response Assessment in Neuro-Oncology (RANO) classification (based upon residual contrast-enhancing (CE) and non-CE tumor), and to (2) define factors consolidating the surgical effects on outcome.

METHODS:

The RANO resect group retrospectively compiled an 8-center cohort of patients with first recurrence from previously resected glioblastomas. The associations of re-resection and other clinical factors with outcome were analyzed. Propensity score-matched analyses were constructed to minimize confounding effects when comparing the different RANO classes.

RESULTS:

We studied 681 patients with first recurrence of Isocitrate Dehydrogenase (IDH) wild-type glioblastomas, including 310 patients who underwent re-resection. Re-resection was associated with prolonged survival even when stratifying for molecular and clinical confounders on multivariate analysis; ≤1 cm3 residual CE tumor was associated with longer survival than non-surgical management. Accordingly, "maximal resection" (class 2) had superior survival compared to "submaximal resection" (class 3). Administration of (radio-)chemotherapy in the absence of postoperative deficits augmented the survival associations of smaller residual CE tumors. Conversely, "supramaximal resection" of non-CE tumor (class 1) was not associated with prolonged survival but was frequently accompanied by postoperative deficits. The prognostic role of residual CE tumor was confirmed in propensity score analyses.

CONCLUSIONS:

The RANO resect classification serves to stratify patients with re-resection of glioblastoma. Complete resection according to RANO resect classes 1 and 2 is prognostic.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Neuro Oncol Assunto da revista: NEOPLASIAS / NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Neuro Oncol Assunto da revista: NEOPLASIAS / NEUROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha